CL2023002616A1 - Inhibidores del sarcómero cardíaco - Google Patents
Inhibidores del sarcómero cardíacoInfo
- Publication number
- CL2023002616A1 CL2023002616A1 CL2023002616A CL2023002616A CL2023002616A1 CL 2023002616 A1 CL2023002616 A1 CL 2023002616A1 CL 2023002616 A CL2023002616 A CL 2023002616A CL 2023002616 A CL2023002616 A CL 2023002616A CL 2023002616 A1 CL2023002616 A1 CL 2023002616A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutically acceptable
- cardiac sarcomere
- inhibitors
- tautomer
- stereoisomer
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 210000002235 sarcomere Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Abstract
Se proporcionan compuestos de la Fórmula (I): o un estereoisómero o tautómero de los mismos, o una sal farmacéuticamente aceptable de cualquiera de los precedentes, en donde R1 , R2 , R3 , y R4 han sido definidos en la presente. Además se proporciona una composición farmacéuticamente aceptable que comprende un compuesto de la Fórmula (I), o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los precedentes. Además se proporcionan métodos de uso de un compuesto de la Fórmula (I), o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los precedentes.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156853P | 2021-03-04 | 2021-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023002616A1 true CL2023002616A1 (es) | 2024-02-02 |
Family
ID=80937093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023002616A CL2023002616A1 (es) | 2021-03-04 | 2023-09-01 | Inhibidores del sarcómero cardíaco |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11919909B2 (es) |
| EP (1) | EP4301760A1 (es) |
| JP (1) | JP2024508526A (es) |
| KR (1) | KR20240015622A (es) |
| CN (1) | CN117083275A (es) |
| AR (1) | AR125026A1 (es) |
| AU (1) | AU2022229390A1 (es) |
| BR (1) | BR112023017461A2 (es) |
| CA (1) | CA3209557A1 (es) |
| CL (1) | CL2023002616A1 (es) |
| IL (1) | IL305628A (es) |
| TW (1) | TW202302594A (es) |
| WO (1) | WO2022187501A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| CA3209557A1 (en) | 2021-03-04 | 2022-09-09 | Bradley P. Morgan | Cardiac sarcomere inhibitors |
| WO2024050539A1 (en) * | 2022-09-02 | 2024-03-07 | Cytokinetics, Incorporated | Crystalline forms of 5-(3,4-difluorobenzyl)-8-((1r,4r)-4-methylcyclohexyl)-6,9-dioxo-2,5,8-triazaspiro[3.5]nonane-2-carbaldehyde |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE69535592T2 (de) | 1994-03-25 | 2008-06-12 | Isotechnika, Inc., Edmonton | Verbesserung der effektivität von arzneimitteln duren deuterierung |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| JP4613157B2 (ja) | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
| ES2378620T3 (es) | 2003-03-27 | 2012-04-16 | Cytokinetics, Inc. | Sulfonamidas para el tratamiento de insuficiencia cardiaca congestiva, sus composiciones y usos. |
| WO2004094424A1 (ja) | 2003-04-21 | 2004-11-04 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその用途 |
| PL1765327T3 (pl) | 2004-06-17 | 2015-01-30 | Cytokinetics Inc | Związki, kompozycje i sposoby |
| EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| MX2007012883A (es) | 2005-04-22 | 2007-12-10 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| ES2459468T3 (es) | 2009-05-15 | 2014-05-09 | Novartis Ag | Arilpiridinas como inhibidores de aldosterona sintasa |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| PL2804865T3 (pl) | 2012-01-20 | 2016-06-30 | Idorsia Pharmaceuticals Ltd | Heterocykliczne pochodne amidowe jako antagoniści receptora p2x7 |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| CN105473576B (zh) | 2013-06-21 | 2018-10-30 | 迈奥卡迪亚公司 | 针对心脏病症的嘧啶二酮化合物 |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| CN104539229A (zh) | 2014-12-26 | 2015-04-22 | 金海新源电气江苏有限公司 | 一种太阳能光伏支架 |
| MX2022007040A (es) | 2015-01-22 | 2022-06-24 | Myokardia Inc | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd). |
| CN108430997B (zh) | 2015-12-17 | 2021-06-04 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| EP3390398A1 (en) | 2015-12-18 | 2018-10-24 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| WO2017190107A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| JOP20190058B1 (ar) | 2016-09-27 | 2023-09-17 | Merck Sharp And Dohme Llc | مشتقات كرومان، أيزوكرومان وداي هيدرو أيزو بنزوفوران كمُعدلات تفارغية سالبة mGluR2، تركيبات، واستخدامها |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| MA49760A (fr) | 2017-08-04 | 2020-06-10 | Myokardia Inc | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| IL277071B1 (en) | 2018-03-08 | 2024-03-01 | Incyte Corp | Aminopyrizine diol compounds as PI3K–y inhibitors |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| KR20210068422A (ko) | 2018-08-31 | 2021-06-09 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| PE20211066A1 (es) | 2018-08-31 | 2021-06-09 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| CN114765954B (zh) | 2019-07-17 | 2024-01-02 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂口服制剂 |
| AU2020378197A1 (en) | 2019-11-10 | 2022-05-26 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| CA3190060A1 (en) | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843A (zh) | 2020-11-19 | 2022-05-20 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| KR20230110538A (ko) | 2020-11-20 | 2023-07-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| WO2022111498A1 (zh) | 2020-11-24 | 2022-06-02 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CA3209557A1 (en) | 2021-03-04 | 2022-09-09 | Bradley P. Morgan | Cardiac sarcomere inhibitors |
-
2022
- 2022-03-03 CA CA3209557A patent/CA3209557A1/en active Pending
- 2022-03-03 WO PCT/US2022/018725 patent/WO2022187501A1/en active Application Filing
- 2022-03-03 IL IL305628A patent/IL305628A/en unknown
- 2022-03-03 BR BR112023017461A patent/BR112023017461A2/pt unknown
- 2022-03-03 EP EP22712689.3A patent/EP4301760A1/en active Pending
- 2022-03-03 AR ARP220100486A patent/AR125026A1/es unknown
- 2022-03-03 JP JP2023553393A patent/JP2024508526A/ja active Pending
- 2022-03-03 TW TW111107659A patent/TW202302594A/zh unknown
- 2022-03-03 CN CN202280017911.8A patent/CN117083275A/zh active Pending
- 2022-03-03 AU AU2022229390A patent/AU2022229390A1/en active Pending
- 2022-03-03 US US17/685,778 patent/US11919909B2/en active Active
- 2022-03-03 KR KR1020237033052A patent/KR20240015622A/ko unknown
-
2023
- 2023-09-01 CL CL2023002616A patent/CL2023002616A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3209557A1 (en) | 2022-09-09 |
| IL305628A (en) | 2023-11-01 |
| CN117083275A (zh) | 2023-11-17 |
| AR125026A1 (es) | 2023-05-31 |
| TW202302594A (zh) | 2023-01-16 |
| KR20240015622A (ko) | 2024-02-05 |
| BR112023017461A2 (pt) | 2023-09-26 |
| WO2022187501A1 (en) | 2022-09-09 |
| US20220306642A1 (en) | 2022-09-29 |
| EP4301760A1 (en) | 2024-01-10 |
| JP2024508526A (ja) | 2024-02-27 |
| US11919909B2 (en) | 2024-03-05 |
| AU2022229390A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco | |
| ECSP20044709A (es) | Inhibidores de sarcómero cardíaco | |
| CL2021000481A1 (es) | Inhibidores de sarcómeros cardíacos. | |
| UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| RU2021139070A (ru) | Ингибиторы ERBB/BTK | |
| DK1261602T3 (da) | Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
| AR120029A1 (es) | Compuestos heterocíclicos | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| ECSP23089582A (es) | Compuestos de espiroindolinona como bloqueadores del canal agitador de potasio kv1.3 | |
| AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
| CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| AR128066A1 (es) | Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos | |
| CO2024005362A2 (es) | Compuestos de cd73 | |
| ECSP23073998A (es) | Compuestos heterocíclicos de arilo como bloqueadores del canal agitador de potasio kv1.3 | |
| AR120811A1 (es) | Inhibidores de proteínas kras mutantes | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso | |
| AR127559A1 (es) | Compuestos, composiciones y métodos | |
| AR124698A1 (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| AR114263A1 (es) | Compuestos terapéuticos y métodos para utilizarlos | |
| AR114394A1 (es) | Inhibidores de arginasa y sus métodos de uso | |
| EA202091733A1 (ru) | Аналоги дигидробензофурана и индена в качестве ингибиторов саркомера сердца |